Fox Chase Cancer Center News

PHILADELPHIA (June 3, 2024) — A new integrated palliative care rotation for hematology/oncology fellows improved their palliative care knowledge and skill confidence, according to results of a pilot study presented today by Fox Chase Cancer Center researchers at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

PHILADELPHIA (May 31, 2024) — Fox Chase Cancer Center and Temple Health researchers will participate in the presentation and discussion of six research projects and two other speaking engagements at the 2024 American Society of Clinical Oncology Annual Meeting, which is being held May 31-June 4 in Chicago.

PHILADELPHIA (May 29, 2024) — Researchers at Fox Chase Cancer Center have documented the first case of rectal myxoid leiomyosarcoma (MLS), a rare cancer typically seen in the female reproductive system. The researchers also found a novel fusion gene that can be used to positively identify the cancer at the molecular level.

PHILADELPHIA (May 23, 2024) — Here at Temple Health, we’re no stranger to firsts—whether that means performing a pioneering surgery, opening a new type of facility, or offering a groundbreaking treatment. That’s why it’s no surprise that we’re also leading the way in Urology care, reinforced by the recent launch of the Fox Chase-Temple Urologic Institute.

PHILADELPHIA (May 20, 2024) — Pancreatic cancer patients who received single modality neoadjuvant therapy experienced fragmented care, which is care at multiple centers, more often compared with those who received total neoadjuvant therapy, according to a study from researchers at Temple University Hospital and Fox Chase Cancer Center. The research was presented today at Digestive Disease Week (DDW).

PHILADELPHIA (May 20, 2024) — Adjuvant therapy in patients with clinical T2N0 rectal cancer may currently be underutilized, according to the findings of a study from researchers at Temple University Hospital and Fox Chase Cancer Center. The research was presented yesterday at Digestive Disease Week (DDW).

PHILADELPHIA (May 17, 2024) — Fox Chase Cancer Center and the Fox Chase - Temple Urologic Institute are proud to welcome patients to the newly renovated and expanded clinical space located on the third floor of Fox Chase - Huntingdon Pike, which is located at 50 Huntingdon Pike in Rockledge, Pennsylvania. These renovations are aimed at significantly improving care for urology and urologic oncology patients both within the region and beyond.

Daniel M. Geynisman, MD, Chief of the Division of Genitourinary Medical Oncology and an Associate Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, has been appointed Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network. The National Comprehensive Cancer Network (NCCN) is a nonprofit alliance of leading cancer centers devoted to patient care, research, and education.